The Düsseldorf Regional Court has found that Praluent (alirocumab) infringes the German part of US biotech firm Amgen’s (Nasdaq: AMGN) European patent (EP 2 215 124), relating to rival product Repatha (evolocumab), directed to antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).
The court granted an injunction prohibiting French pharma major Sanofi (Euronext: SAN) and partner Regeneron Pharmaceuticals’ (Nasdaq: REGN) from manufacture, sale and marketing of Praluent in Germany. For the injunction to go into effect, Amgen must enforce it by posting a bond.
Sanofi and Regeneron said: “We are disappointed in this decision, and continue to believe that patients and physicians should have a choice of cholesterol-lowering therapies in order to achieve optimal lipid-lowering for patients.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze